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inappropriate use in 7%-46% of patients. The analysis was limited to drug prescrip-
tion costs and excluded other costs affected by the recommendations, resulting in 
forecasted savings ranging from $7-$16 million over a 3-year period. JSS Medical 
Research performed the BIA from the ministry of health perspective. Methods: 
Our hybrid epidemiological and claims-based BIA included costs of TRTs and key 
cost drivers of physician visits, administering injectable TRTs, testosterone level 
testing and Exceptional Access Program evaluation and processing. Ontario pre-
scription drug expenditures based on claims data, as well as published literature 
and expert opinion were utilized. We evaluated the impact of the ODPRN scenarios 
with and without inappropriate TRT use over a 3-year period. Results: Based on 
the JSS assumption of all patients qualifying for TRT and taking into consideration 
key cost drivers, option B would cost $1.01 million; option C $766,000, and option D 
$252,000. Using ODPRN assumptions of inappropriate use, JSS forecasted savings 
of $373,000-$13.4 million as opposed to savings of $7-$16 million forecasted by 
the ODPRN. ConClusions: ODPRN savings exclude key cost drivers and assume 
a greater magnitude of inappropriate use. The burden of the policy change could 
completely offset savings and generate costs of up to $1 million to the healthcare 
budget. Healthcare policy recommendations based on drug costs alone underesti-
mate the true cost, shifting and in this case creating additional costs to other areas 
of the healthcare system.
PDB119
Do Access RestRictions AlwAys imPly cost ReDuction? cAse of 
tuRkish DPP4 mARket in tReAtment of tyPe ii DiABetes
Erdogan Ciftci E1, Dokuyucu O1, Saylan M1, Keskinaslan A2
1Novartis, Istanbul, Turkey, 2Novartis AG, Istanbul, Turkey
objeCtives: Treatment guidelines propose stepwise approach for type II diabe-
tes management: metformin (Met) as first, Met + SUs or other oral antidiabetic 
agents (i.e. DPP4s) or insulin as second or third line. Despite this evidence based 
line treatment, DPP4s prescriptions in Turkey can be initiated only by endocrinol-
ogy or internal medicine specialists working on tertiary care since March 2010 to 
control DM treatment budget. This access restriction may naturally cause prescrip-
tion shifts to non-restricted treatment options such as insulins. This research’s 
objective is comparing yearly usage ratio of insulins and DPP4s in Turkey and 5 
European Turkey’s price reference countries. Methods: Sales as international 
units(IU) and value between 2010-2014 are obtained from IMS Dataview7. Yearly 
total insulin vs. DPP4s as IU/SU and US$ sales is compared between Turkey and 
France, Greece, Italy, Portugal, Spain. Results: Insulin to DPP4s utilization ratio 
in Turkey(183) is 4,6 times higher than reference countries’ average (40) in 2014. 
Compared to 5 EU countries, total insulin to DPP4s utilization ratio is consist-
ently the highest (540 in 2010 and 183 in 2014) in Turkey between 2010-2014. As 
value sales, the highest ratio of total insulin to DPP4s is in Turkey (7,2), followed 
by Italy(2,9) and France(1,3). In Portugal, Spain and Greece this ratio is below one, 
indicating higher DPP4 value sales compared to insulins. Reversed ratio of insulin 
to DPP4s in Turkey is also present between 2010-2013. ConClusions: Turkey has 
the highest insulin to DPP4 ratio over five years among other countries. DPP4s 
access restriction might have caused early and disproportionate insulinization 
of patients. From health policy perspective, implementation of access restriction 
might have led cost reduction in the short run, however it may cause greater 
burden due to shifts to later treatment lines.
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objeCtives: Diabetes is a chronic condition for which effective medications must 
be taken continuously (i.e. patient must be observant). Research shows that intro-
ducing user fees may reduce patient observance. However, there is little evidence 
that providing free medications improves diabetic patient observance. Taking advan-
tage of a change in Quebec (Canada) policy the objective of this study was to assess 
whether the return to free medications (RFM) improved diabetic patient obser-
vance. Methods: This study used a pretest-posttest design: drug use by diabetic 
patients in the 3 years prior to RFM was compared to their drug use in the 2 years 
following RFM. Data came from the Quebec public drug plan (QPDP) for three groups: 
social welfare recipients, elderly receiving full guaranteed revenue supplement (GRS) 
and those receiving partial GRS. Data on oral antidiabetic drug consumption were 
obtained for a random sample of patients that were covered by the QPDP during the 
full five year period (N total = 3308). Two indicators of observance were measured: 
whether a patient was using antidiabetic drugs at least 80% of days and the propor-
tion of days where antidiabetic drugs were used. These were measured both for the 
12 months following the first prescription prior to RFM and after RFM and for the 
whole pre-RFM and post-RFM periods. To compare pre and post RFM data, we used 
Chi-square test for the first indicator and t-test for the second indicator. Results: 
The proportion of patients who were observant was significantly (p< 0.001) higher 
after RFM compared to before RFM, both for 12 months (87.3% vs. 82.8%) and the 
whole period (85.3% vs. 83.7%). The proportion of days where antidiabetic drugs were 
used also was significantly higher (92.3% vs. 89.2%; 90.8% vs 86.6%). ConClusions: 
Providing free medications to diabetic patients raised their observance and may 
have improved patient outcomes.
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objeCtives: According to the literature, there is a gap between the results of clini-
cal trials (efficacy) and the effects of the same intervention in real-life (effective-
ness). Although this so-called “efficacy-effectiveness gap” is often mentioned in 
studies was intermediate (score: 17 of 28). Almost all studies examined objective 
health measures, with most indicating non-significant differences between the 
Maps™ intervention and the control group/s. Mixed results were found regarding 
the influence on HbA1c. The majority of studies reported no significant change in 
blood pressure and mixed results were found regarding other health indicators. Only 
five studies examined subjective measures and eight assessed the effects on health 
behaviors, mostly reporting non-significant or positive findings. ConClusions: 
This review provides evidence about the limited number and relatively low quality 
of studies, which examined the influence of Maps™ on health outcomes. Although 
Maps™ hold the potential to improve health outcomes, there is a need to develop 
well-designed large sample studies that enable to draw more conclusive results.
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objeCtives: Type 1 diabetes mellitus (T1DM) affects approximately 400,000 people 
in the UK, amounting to £1.8 billion in direct healthcare costs in 2012. Statistics 
from the 2012/13 national diabetes audit (NDA) suggest that 92.4% of T1DM patients 
in England fail to achieve target haemoglobin A1c (HbA1c) levels (< 48 mmol/mol 
[6.5%]). Current NICE draft guidance recognises the importance of education on 
glycaemic control; recommending courses for all T1DM patients within one year of 
diagnosis. However, only 4.1% of newly-diagnosed diabetics are offered structured 
courses such as the Dose Adjustment for Normal Eating (DAFNE). We sought to 
determine the relationship between educational course availability and uptake, 
and target HbA1c achievement. Methods: Educational course attendance data 
and HbA1c results for T1DM patients was extracted from the 2012/13 NDA for 9 
regions in England, and DAFNE centre location records for 2014 were obtained. We 
explored the relationship between educational course uptake and optimal HbA1c 
achievement in newly-diagnosed patients, and also the number of DAFNE cen-
tres against overall T1DM HbA1c achievement. Results: Newly-diagnosed T1DM 
patients consistently manage HbA1c better than the overall T1DM population. 
However, no association was found between education course uptake or the number 
of DAFNE centres per region, and optimal HbA1c achievement in newly-diagnosed 
patients. A weak positive correlation was found between the number of DAFNE 
locations, and patients in the overall T1DM population achieving optimal HbA1c 
(R2= 0.3). ConClusions: Educational courses may help T1DM patients achieve bet-
ter glycaemic control. However, uptake for courses is below current NICE draft rec-
ommendations. Increasing uptake for such courses could help improve target HbA1c 
achievement in the long-term, whilst also providing a societal benefit through cost 
savings. Examining potential socio-economic factors and their impact on course 
uptake could be investigated. More research is required into educational course 
uptake in the overall T1DM population.
PDB117
DiABetes in tuRkey: AnAlysis of PAtient chARActeRistics
Demir C, Gursoy K, Koselerli R, Ozturk Y, Suzen A
Turkish Social Security Institution, Ankara, Turkey
objeCtives: As the number of people with diabetes grows worldwide, it becomes 
a challenging problem for public health budgets. The objective of this study is to 
investigate and analyze the main characteristics of diabetes in Turkey. Methods: 
Claims data from Turkish Social Security Institution were collected for the diagnosed 
patients having insulin dependent (IDD) and non-insulin dependent diabetes (NIDD) 
between 2010 and 2014. Prevalence, incidence, age and gender distribution, and 
mortality figures were aggregated and analyzed in order to show how the disease is 
evolving. Results: Number of patients diagnosed with diabetes between 2010 and 
2014 totaled 3.1 million; nearly 85% with NIDD and 60% were females. On average 
645,000 new patients were added yearly. The incidence of diabetes dropped from 
0.94% to 0.76% in 2010-2014, where IDD and NIDD were 0.06% and 0.71% in 2014 
respectively. While the share of NIDD patients represented 81% in 2010, the figure 
hiked 90% in 2014. When it comes to age distribution, 46-64 age group received 
the largest share (48%) among all patients, followed by 25-45 and 65+ age groups, 
all three constituting nearly 96%. The average age of first diagnosis for male and 
female were 58.6 and 59.4 respectively, signaling that the disease is late diagnosed 
compared to other countries. In addition, 21% of females and %14 of males died 
over four-year time and average age of death was nearly the same in both diabetes 
types. ConClusions: Despite the decline in the incidence, diabetes epidemic is 
expected to grow in the future with lower mortality rates. Late diagnosis of diabe-
tes seems to be the most important problem in Turkey. Then, immediate action is 
needed for new strategies such as yearly monitoring and public education programs 
to reach out patients earlier.
PDB118
the imPAct of heAlthcARe Policy BAseD on DRug PlAn PeRsPective 
veRsus the ministRy of heAlth PeRsPective: A cAse stuDy of 
the oDPRn RecommenDAtions of RestRicting ReimBuRsement of 
testosteRone RePlAcement theRAPy foR hyPogonADism in ontARio, 
cAnADA
Hubert MM1, Karellis A1, Stutz M1, Grober E2, Greenberg D3, Sampalis JS4
1JSS Medical Research, Saint-Laurent, QC, Canada, 2Mount Sinai Hospital, Toronto, ON, Canada, 
3Saint-Joseph Health Center, Toronto, ON, Canada, 4JSS Medical Research Inc., St-Laurent, QC, 
Canada
objeCtives: The Ontario Drug Policy Research Network (ODPRN) published recom-
mendations to restrict reimbursement and coverage criteria of testosterone replace-
ment therapy (TRT) in Ontario. The ODPRN’s budget impact analysis (BIA) evaluated: 
no reimbursement change (option A), restricting coverage of all forms of TRT (option 
B), restricting oral and topical forms only (option C), or restricting topical forms 
only (option D). The analysis assumed exponential growth of TRT expenditures and 
